BioMarin Pharmaceuticals
BMRN
390 hedge funds and large institutions have $13.3B invested in BioMarin Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 161 increasing their positions, 121 reducing their positions, and 53 closing their positions.
44% more funds holding in top 10
Funds holding in top 10: 9 → 13 (+4)
41% more call options, than puts
Call options by funds: $119M | Put options by funds: $84.2M
33% more repeat investments, than reductions
Existing positions increased: 161 | Existing positions reduced: 121
9% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 53
1% more funds holding
Funds holding: 388 → 390 (+2)
21% less capital invested
Capital invested by funds: $16.9B → $13.3B (-$3.59B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal London Asset Management
United Kingdom
|
+$251M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$173M |
| 3 |
Jennison Associates
New York
|
+$167M |
| 4 |
O
OrbiMed
New York
|
+$71.1M |
| 5 |
FAM
Fred Alger Management
New York
|
+$70M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$174M |
| 2 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$166M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$147M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$93.6M |
| 5 |
JP Morgan Chase
New York
|
-$93.1M |
BMRN Hedge Fund Activity: Q1 2016 in Review
390 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2016, worth a combined $13.3B — down 21% from $16.9B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new BMRN positions and 53 closed out — a net gain of 5 holders — while 161 added to existing stakes and 121 trimmed.
The largest buyer was Royal London Asset Management, adding an estimated $251M. The largest seller was Capital Research Global Investors, cutting an estimated $174M.
- 390 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2016, up from 388 in Q4 2015.
- Funds reported $13.3B of BioMarin Pharmaceuticals stock for Q1 2016, down 21% quarter-over-quarter.
- 58 funds opened new BioMarin Pharmaceuticals positions in Q1 2016 and 53 closed out, a net change of +5 holders.
- The largest BioMarin Pharmaceuticals buyer in Q1 2016 was Royal London Asset Management, an estimated $251M added.
- The largest BioMarin Pharmaceuticals seller in Q1 2016 was Capital Research Global Investors, an estimated $174M sold.
Based on aggregated 13F filings for Q1 2016.